These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 6192350

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Single injection of three different preparations of alpha-interferon modifies morphine abstinence signs for a prolonged period.
    Dafny N, Reyes-Vazquez C.
    Int J Neurosci; 1987 Feb; 32(3-4):953-61. PubMed ID: 3596938
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Neurotropin suppression of the manifestations of the naloxone-provoked withdrawal syndrome in morphine-dependent rats].
    Sudakov SK, Konstantinopol'skiĭ MA, Surkova LA, Tiurina IV, Konishi J, Yumia H.
    Farmakol Toksikol; 1991 Feb; 54(4):16-8. PubMed ID: 1786813
    [Abstract] [Full Text] [Related]

  • 7. [The effect of GABA-positive agents on the formation of morphine dependence and on the manifestations of a withdrawal syndrome].
    Belozertseva IV, Andreev BV.
    Eksp Klin Farmakol; 2000 Feb; 63(1):19-23. PubMed ID: 10763104
    [Abstract] [Full Text] [Related]

  • 8. Cyclophosphamide and cortisol reduce the severity of morphine withdrawal.
    Montgomery SP, Dafny N.
    Int J Immunopharmacol; 1987 Feb; 9(4):453-7. PubMed ID: 3623770
    [Abstract] [Full Text] [Related]

  • 9. The effects of laboratory handling procedures on naloxone-precipitated withdrawal behavior in morphine-dependent rats.
    Pierce TL, Raper C.
    J Pharmacol Toxicol Methods; 1995 Nov; 34(3):149-55. PubMed ID: 8573765
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice.
    Zhang G, Wu X, Zhang YM, Liu H, Jiang Q, Pang G, Tao X, Dong L, Stackman RW.
    Neuropharmacology; 2016 Feb; 101():246-54. PubMed ID: 26432939
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The severity of naloxone-precipitated opiate withdrawal is attenuated by felbamate, a possible glycine antagonist.
    Kosten TA, DeCaprio JL, Rosen MI.
    Neuropsychopharmacology; 1995 Dec; 13(4):323-33. PubMed ID: 8747757
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Distinct regulation pattern of Egr-1, BDNF and Arc during morphine-withdrawal conditioned place aversion paradigm: Role of glucocorticoids.
    García-Pérez D, Ferenczi S, Kovács KJ, Milanés MV.
    Behav Brain Res; 2019 Mar 15; 360():244-254. PubMed ID: 30550948
    [Abstract] [Full Text] [Related]

  • 18. Opiate withdrawal signs precipitated by naloxone following a single exposure to morphine: potentiation with a second morphine exposure.
    Schulteis G, Heyser CJ, Koob GF.
    Psychopharmacology (Berl); 1997 Jan 15; 129(1):56-65. PubMed ID: 9122364
    [Abstract] [Full Text] [Related]

  • 19. Selective mGlu5 receptor antagonist MTEP attenuates naloxone-induced morphine withdrawal symptoms.
    Pałucha A, Brański P, Pilc A.
    Pol J Pharmacol; 2004 Jan 15; 56(6):863-6. PubMed ID: 15662102
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.